Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
2017 · Infectious Diseases and Therapy · 18 citations
https://doi.org/10.1007/s40121-017-0178-6
K
Kimmie McLaurin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
84
Papers
1.7K
Citations
19
h-index
25
i10-index
Kimmie McLaurin is an academic researcher from AstraZeneca (France). The author has contributed to research in topics: Respiratory viral infections research & Neonatal Respiratory Health Research & PARP inhibition in cancer therapy. The author has an h-index of 19, co-authored 72 publications.
ORCID: 0000-0003-2939-0455Papers by this author
worksUtilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
2021 · Advances in Therapy · 17 citations
https://doi.org/10.1007/s12325-021-01959-5
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
2020 · PharmacoEconomics · 8 citations
https://doi.org/10.1007/s40273-020-00949-9
Validation of an Administrative Claims-based Line of Therapy Algorithm for Women with Ovarian Cancer Using Medical Chart Review
2025 · Advances in Therapy · 3 citations
https://doi.org/10.1007/s12325-025-03174-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat